Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin alfa Megalabs vs Epogen in CKD Anemia
NCT06352138Phase 3Not yet recruiting
- Sponsor
- Megalabs
- Start
- Jul 2025
- Primary completion
- Mar 2027
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of epoetin alfa in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Megalabs. Primary endpoints: Mean Absolute Change in Hemoglobin Levels at 18 months and Change in Mean Hb Level at 18 months. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
epoetin alfa
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT06352138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06352138.